Vice President, Clinical Development
Elizabeth J. Ackermann, Ph.D. joined Otonomy as our Vice President, Clinical Development in March 2019. Dr. Ackermann has 20 years of pharmaceutical development experience in neurology and rare diseases. Prior to Otonomy, she served as the Chief Science Officer at the Myotonic Dystrophy Foundation. Previously, she held various leadership positions at Ionis Pharmaceuticals including Vice President, Clinical Development where she led the development of Tegsedi® (inotersen), an approved treatment for Transthyretin Amyloidosis with Polyneuropathy, from Phase 1 to regulatory submissions. She also previously served as a Project Manager at Synteract, a clinical contract research organization, and held various leadership positions in research at TorreyPines Therapeutics, a biotechnology company focused on Alzheimer’s disease and pain. Dr. Ackermann worked as a post-doctoral fellow at Ionis Pharmaceuticals and as a NIH post-doctoral fellow in pharmacology at University of California, San Diego. She received her Ph.D. in Biochemistry from University of California, San Diego and Bachelor’s degree in Chemistry from Sonoma State University.